Dermata Therapeutics, Inc.
DRMA
$5.50
-$0.33-5.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 1.06M | 1.01M | 824.30K | 874.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.77M | 2.34M | 3.20M | 3.23M | 2.88M |
| Operating Income | -1.77M | -2.34M | -3.20M | -3.23M | -2.88M |
| Income Before Tax | -1.70M | -2.30M | -3.15M | -3.17M | -2.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.70M | -2.30M | -3.15M | -3.17M | -2.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.70M | -2.30M | -3.15M | -3.17M | -2.83M |
| EBIT | -1.77M | -2.34M | -3.20M | -3.23M | -2.88M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.66 | -4.47 | -9.17 | -20.41 | -41.82 |
| Normalized Basic EPS | -1.04 | -2.79 | -5.73 | -12.76 | -26.14 |
| EPS Diluted | -1.66 | -4.47 | -9.17 | -20.41 | -41.82 |
| Normalized Diluted EPS | -1.04 | -2.79 | -5.73 | -12.76 | -26.14 |
| Average Basic Shares Outstanding | 1.03M | 515.50K | 343.70K | 155.50K | 67.70K |
| Average Diluted Shares Outstanding | 1.03M | 515.50K | 343.70K | 155.50K | 67.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |